The Severity of Newly Diagnosed Asthma Patients and the Result of Initial 12 Weeks Treatment in China

AstraZeneca4,817 enrolled

Overview

The primary objective of the NIS is to evaluate the severity of newly diagnosed asthma patients based on Global Initiative for Asthma (GINA) severity category (GINA 2006 update).

This is a multi-centre, prospective non-interventional study planned to be conducted in China. The study aims to recruit about 5000 newly diagnosed patients from about 50 tier 3 hospitals with respiratory department. Each site recruits about 50-150 patients. The primary variable will be distribution of severity based on GINA definition (GINA 2006 update) at baseline in the total population. There will be 4 visits for this study, Informed consent and following study procedures (ACQ-5(asthma control questionnaire), severity assessment) will be done at visit 1. After that, according to clinical practice in China patients usually go to the clinic every 4 weeks. Asthma control status, ACQ-5 and sever exacerbation will be assessed at each clinic visit till 12 weeks (visit 2, 3, 4).

Study Type

OBSERVATIONAL

Enrollment

4,817

Conditions

Asthma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Newly diagnosed asthma patients who are not on inhaled gluococorticosteroid within 3 months. 2. Out-patient with an age of 18 years and above 3. Signed and dated informed consent The prescription of the medicinal product is clearly separated from the decision to include the subject in the NIS. Generally, asthma medication refers to those recommended in GINA guideline (GINA2012 update) and decided by investigator. Exclusion Criteria: 1. Participating in any clinical trial during the last 90 days 2. Have COPD 3. With asthma exacerbation

Locations (30)

Research Site

Baotou, China

Research Site

Beijing, China

Outcomes

Primary Outcomes

Asthma Severity assessment based on GINA definition (GINA 2006 update) at baseline in the total population

severity based on GINA definition (GINA 2006 update) at baseline in the total population.

Time frame: Day 1

Secondary Outcomes

evaluate the control level of initial 12 weeks treatment based on Assessment of Current Clinical Control in GINA (GINA 2012 update).

The asthma control status assessment will be based on Assessment of Current Clinical Control in GINA (GINA 2012 update).

Time frame: up to 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.